S Mukaddam-Daher
Overview
Explore the profile of S Mukaddam-Daher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aceros H, Farah G, Cobos-Puc L, Stabile A, Noiseux N, Mukaddam-Daher S
Br J Pharmacol
. 2011 Mar;
164(3):946-57.
PMID: 21426316
Background And Purpose: Regression of left ventricular hypertrophy by moxonidine, a centrally acting sympatholytic imidazoline compound, results from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation....
2.
Paquette P, Duguay D, El-Ayoubi R, Menaouar A, Danalache B, Gutkowska J, et al.
Br J Pharmacol
. 2007 Dec;
153(3):459-67.
PMID: 18059325
Background And Purpose: Left ventricular hypertrophy (LVH) is a maladaptive process associated with increased cardiovascular risk. Regression of LVH is associated with reduced complications of hypertension. Moxonidine is an antihypertensive...
3.
Jankowski M, Wang D, Mukaddam-Daher S, Gutkowska J
J Endocrinol
. 2005 Jan;
184(1):209-17.
PMID: 15642797
Cyclic guanosine monophosphate (cGMP), which is implicated in cardiac cell growth and function, is synthesized by cytoplasmic soluble guanylyl cyclase (GC) stimulated via nitric oxide (NO) and by particulate membrane-bound...
4.
Gutkowska J, Mukaddam-Daher S, Jankowski M, Schiller P
J Cardiovasc Pharmacol
. 2004 Nov;
44(6):651-8.
PMID: 15550783
The cardiovascular and renal effects of a mu opioid agonist, [Dmt]DALDA, were studied in conscious Sprague-Dawley rats. During the first hour postinjection, [Dmt]DALDA (0.025-250 microg/rat, IV) evoked a dose-dependent diuresis....
5.
Mukaddam-Daher S, Gutkowska J
Braz J Med Biol Res
. 2004 Jul;
37(8):1239-45.
PMID: 15273826
Chronic stimulation of sympathetic nervous activity contributes to the development and maintenance of hypertension, leading to left ventricular hypertrophy (LVH), arrhythmias and cardiac death. Moxonidine, an imidazoline antihypertensive compound that...
6.
El-Ayoubi R, Menaouar A, Gutkowska J, Mukaddam-Daher S
Ann N Y Acad Sci
. 2004 Mar;
1009:274-8.
PMID: 15028599
The effect of treatment with moxonidine (120 mg/kg/h sc, 4 weeks) on cardiac I(1)-receptors and natriuretic peptide synthesis was evaluated in spontaneously hypertensive rats (SHR). I(1)-receptor protein (85 kD) was...
7.
Mukaddam-Daher S, Menaouar A, El-Ayoubi R, Gutkowska J, Jankowski M, Velliquette R, et al.
Ann N Y Acad Sci
. 2004 Mar;
1009:244-50.
PMID: 15028594
Moxonidine, an imidazoline receptor agonist that acts centrally to inhibit sympathetic activity, has been shown to reduce effectively blood pressure, fasting insulin levels, and free fatty acids. In this study,...
8.
Mukaddam-Daher S, Jankowski M, Wang D, Menaouar A, Gutkowska J
J Endocrinol
. 2002 Oct;
175(1):211-6.
PMID: 12379505
We have recently uncovered the presence of an oxytocin system in the heart and found that oxytocin is a physiological regulator of atrial natriuretic peptide (ANP), a diuretic, natriuretic and...
9.
Mukaddam-Daher S, Yin Y, Roy J, Gutkowska J, Cardinal R
Hypertension
. 2001 Aug;
38(2):292-6.
PMID: 11509492
We have previously shown that oxytocin receptors are present in the heart and that perfusion of isolated rat hearts with oxytocin results in decreased cardiac flow rate and bradycardia. The...
10.
Mukaddam-Daher S, Gutkowska J
Hypertension
. 2000 Jun;
35(6):1215-20.
PMID: 10856266
Moxonidine, an antihypertensive imidazoline compound, reduces blood pressure by selective activation of central imidazoline I(1)-receptors and inhibition of sympathetic nerve activity and by direct actions on the kidney, with both...